Disease or Syndrome – Page 72

Roivant’s Kinevant Discontinues Namilumab Development for Pulmonary Sarcoidosis After Phase 2 Failure

9 months ago talkbio0Tagged Drug Development, Failure (biologic function), Kinevant, namilumab, Phase 2 clinical trial, Roivant, Sarcoidosis, Pulmonary

Roivant Sciences, Kinevant, namilumab, pulmonary sarcoidosis, Phase 2 clinical trial, RESOLVE-Lung study, drug development failure

Pliant Therapeutics Halts Phase 2b/3 Idiopathic Pulmonary Fibrosis Trial Following Safety Committee Recommendation

9 months ago talkbio0Tagged BEACON-IPF, bexotegrast, Clinical Trials, Data Safety, Idiopathic Pulmonary Fibrosis, Pliant

Pliant Therapeutics, bexotegrast, idiopathic pulmonary fibrosis (IPF), BEACON-IPF trial, clinical trial suspension, Data Safety Monitoring Board (DSMB)

Relmada Acquires Promising Tourette’s Syndrome Drug Candidate from Asarina Pharma

9 months ago talkbio0Tagged Acquisition, Asarina, asset, CNS disorder, Neurosteroids, Pharma, Phase 2b, Pregnanolone, (3beta, 5alpha)-isomer, Relmada, Tourette 's syndrome

Relmada Therapeutics, Asarina Pharma, Sepranolone, Tourette’s syndrome, neurosteroid, Phase 2b, asset acquisition, CNS disorders

AI-Driven Discovery Unveils Novel Antimicrobial Proteins Effective Against Bacterial and Fungal Infections in Mice

9 months ago talkbio0Tagged Artificial Intelligence, Bacterial Infections, Drug Discovery, in vivo studies, Microbicides, Mycoses, Peptides, protein compounds

Artificial intelligence, protein compounds, antimicrobial peptides, drug discovery, bacterial infections, fungal infections, in vivo studies

Roivant Halts Lung Disease Drug Development as Bio-Thera and Intas Forge Biosimilar Partnership

9 months ago talkbio0Tagged Accord BioPharma, Bio-Thera, Biopharma, Biosimilars, golimumab, Intas, namilumab, Roivant, Sarcoidosis, Pulmonary, Solutions

Roivant Sciences, namilumab, pulmonary sarcoidosis, Bio-Thera Solutions, Intas Pharmaceuticals, golimumab biosimilar, BAT2506, Accord BioPharma

Pliant Therapeutics Halts Key Fibrosis Drug Trial, Stock Plummets Amid Uncertainty

9 months ago talkbio0Tagged BEACON-IPF, bexotegrast, Clinical Trials, crash, Data Safety, Idiopathic Pulmonary Fibrosis, Pliant, Preventive monitoring

Pliant Therapeutics, bexotegrast, idiopathic pulmonary fibrosis, BEACON-IPF trial, clinical trial pause, stock crash, Data Safety Monitoring Board

Sionna Therapeutics Raises $191M in Upsized IPO, Aardvark Therapeutics Aims for $100M Listing

9 months ago talkbio0Tagged biotech, Cystic Fibrosis, IPOs, Metabolic Diseases, Nasdaq, Obesity, Order Tubulidentata (organism)

Biotech IPOs, Sionna Therapeutics, Aardvark Therapeutics, Cystic Fibrosis, Metabolic Diseases, NASDAQ, Obesity Treatment

Roche’s Gazyva Shows Promising Results in Phase III Lupus Nephritis Trial

9 months ago talkbio0Tagged Autoimmune Diseases, Gazyva, Lupus Nephritis, obinutuzumab, Phase III REGENCY trial, Renal function, renal response, Roche (company)

Gazyva, obinutuzumab, lupus nephritis, Phase III REGENCY trial, complete renal response, Roche, autoimmune disease, kidney function

Fourth Patient Receives Gene-Edited Pig Kidney in Groundbreaking Clinical Trial

9 months ago talkbio0Tagged Approved, Clinical Trials, eGenesis, Family suidae, Gene-Edited, Kidney, Kidney Failure, Chronic, Organ Shortage, United States Food and Drug Administration, United Therapeutics, Xenograft procedure

xenotransplantation, clinical trial, gene-edited pig kidney, FDA approval, United Therapeutics, eGenesis, end-stage renal disease, organ shortage

Eli Lilly’s Zepbound Surpasses $4.9 Billion in First Year Sales Despite Q4 Shortfall

9 months ago talkbio0Tagged Advice, earnings, Eli, Eli Lilly, Glucagon-Like Peptide 1, Mounjaro, Obesity, pharmaceutical revenue, Zepbound

Eli Lilly, Zepbound, obesity drug, Q4 2024 earnings, pharmaceutical revenue, GLP-1 medications, Mounjaro, 2025 guidance